<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nader Shaikh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alejandro Hoberman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Urinary tract infections (UTI) are a common and important clinical problem in childhood. Upper urinary tract infections (ie, acute pyelonephritis) may lead to kidney scarring, hypertension, and end-stage kidney disease. Although children with pyelonephritis tend to present with fever, it can be difficult on clinical grounds to distinguish cystitis from pyelonephritis, particularly in young children (those younger than two years) [<a href="#rid1">1</a>]. Thus, we have defined UTI broadly here without attempting to distinguish cystitis from pyelonephritis. Acute cystitis in older children is discussed separately. (See  <a class="medical medical_review" href="/d/html/6012.html" rel="external">"Acute infectious cystitis: Clinical features and diagnosis in children older than two years and adolescents"</a>.)</p><p>The acute management and prognosis of UTI in children will be reviewed here. The epidemiology, risk factors, clinical features, diagnosis, long-term management, and prevention of UTI in children and UTI in newborns are discussed separately. (See  <a class="medical medical_review" href="/d/html/5988.html" rel="external">"Urinary tract infections in children: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/d/html/5990.html" rel="external">"Urinary tract infections in infants and children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6066.html" rel="external">"Urinary tract infections in children: Long-term management and prevention"</a> and  <a class="medical medical_review" href="/d/html/4959.html" rel="external">"Urinary tract infections in neonates"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H3"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goals of treatment for UTI include [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elimination of infection and prevention of urosepsis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relief of acute symptoms (eg, fever, dysuria, frequency)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of recurrence and long-term complications including hypertension, kidney scarring, and impaired kidney growth and function</p><p></p><p>Acute management of UTI in children consists of antimicrobial therapy to treat the acute infection and evaluation for possible predisposing factors (eg, urologic abnormalities). Long-term management centers on prevention of recurrence and complications; it is discussed separately. (See  <a class="medical medical_review" href="/d/html/6066.html" rel="external">"Urinary tract infections in children: Long-term management and prevention"</a>.)</p><p class="headingAnchor" id="H2307660207"><span class="h1">DETERMINING NEED FOR EARLY EMPIRIC ANTIBIOTIC THERAPY</span><span class="headingEndMark"> — </span>We suggest that empiric antimicrobial therapy be initiated immediately in children with a strongly suspected UTI, particularly for those at increased risk for kidney scarring. Suspicion for UTI is based upon demographic and clinical factors (eg, age, sex assigned at birth, circumcision status) and results of the urinalysis (eg, nitrites, leukocyte esterase, white blood cells, and red blood cells) [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/5990.html" rel="external">"Urinary tract infections in infants and children older than one month: Clinical features and diagnosis", section on 'Decision to obtain urine sample'</a>.)</p><p>It is important to collect urine to send for culture and susceptibility <strong>before initiating empiric therapy</strong>. Routine susceptibility testing on the isolated uropathogens will prevent unnecessary delay in administration of definitive therapy.</p><p>Early initiation of antimicrobial therapy is particularly important for children who are at increased risk for kidney scarring if UTI is not promptly treated, including those who present with one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever (especially ≥39°C [102.2°F] or &gt;48 hours)</p><p class="bulletIndent1"><span class="glyph">●</span>Ill appearance</p><p class="bulletIndent1"><span class="glyph">●</span>Costovertebral angle tenderness</p><p class="bulletIndent1"><span class="glyph">●</span>Known immune deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Known urologic abnormality (eg, Grade IV or V vesicoureteral reflux)</p><p></p><p>Early antibiotic therapy (eg, within 72 hours of presentation) may prevent kidney damage. In one study, a delay in the treatment of febrile UTIs was associated with increased risk for kidney scarring; a delay of 48 hours or more increased the odds of new kidney scarring by approximately 47 percent [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4236949523"><span class="h1">DETERMINING TREATMENT SETTING</span><span class="headingEndMark"> — </span>Most children older than two months with UTI who are not vomiting can be safely managed as outpatients as long as close follow-up is possible [<a href="#rid7">7-12</a>]. Close communication with the caregivers should be maintained for the first two to three days of therapy; the seriousness of the infection and the need for completion of the entire course of therapy should be emphasized. (See <a class="local">'Preferred empiric oral regimens'</a> below.)</p><p>Usual indications for hospitalization and/or parenteral therapy (see <a class="local">'Parenteral antibiotics'</a> below) include any of the following [<a href="#rid11">11,13-15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;2 months (see  <a class="medical medical_review" href="/d/html/4959.html" rel="external">"Urinary tract infections in neonates"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical urosepsis (eg, toxic appearance, hypotension, poor capillary refill)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised febrile patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting or inability to tolerate oral medication</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of adequate outpatient follow-up (eg, no telephone, live far from hospital)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to respond to outpatient therapy (see <a class="local">'Response to therapy'</a> below)</p><p></p><p>Although some studies suggest that outpatient management may be considered for select well-appearing infants 29 to 60 days of age [<a href="#rid16">16,17</a>], additional evidence is necessary.</p><p class="headingAnchor" id="H2426684544"><span class="h1">CHOICE OF ANTIBIOTICS</span></p><p class="headingAnchor" id="H100155993"><span class="h2">Recent antibiotic exposure</span><span class="headingEndMark"> — </span>Children receiving antibiotic prophylaxis who have breakthrough UTIs should be treated with a different antimicrobial agent because the organisms are often resistant to the prophylactic antibiotic. Similarly, patients who have been treated with antibiotics for an acute infection within the last two months are also more likely to have a uropathogen that is resistant to that agent; pending culture and susceptibility results, they may require an antibiotic from a different class [<a href="#rid18">18-28</a>]. (See <a class="local">'Second-line empiric oral regimens'</a> below.)</p><p class="headingAnchor" id="H55061661"><span class="h2">Preferred empiric oral regimens</span><span class="headingEndMark"> — </span>We recommend a cephalosporin as the first-line oral agent in the treatment of UTI in children  (<a class="graphic graphic_algorithm graphicRef142108" href="/d/graphic/142108.html" rel="external">algorithm 1</a>) [<a href="#rid7">7,8,29,30</a>].</p><p>The antibiotic of choice should also be guided by local resistance patterns [<a href="#rid18">18,19</a>]; in the United States, these are often available from the antimicrobial stewardship committee of the hospital. The most common bacterial cause of UTI in infants and children is <em>Escherichia coli</em>, and approximately 50 percent of <em>E. coli</em> are resistant to <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a> [<a href="#rid19">19,31-36</a>] (see  <a class="medical medical_review" href="/d/html/5988.html" rel="external">"Urinary tract infections in children: Epidemiology and risk factors", section on 'Microbiology'</a>). Furthermore, the frequency of <em>E. coli</em>-producing extended-spectrum beta-lactamases appears to be increasing [<a href="#rid37">37</a>], resulting in higher rates of resistance to <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>. Rates of resistance to <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) are also increasing in some communities [<a href="#rid18">18,19,32-35,38-42</a>].</p><p>Kidney involvement should be suspected if the child has abnormal urinary findings and one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>High fever (≥39°C [102.2<sup>o</sup>F])</p><p class="bulletIndent1"><span class="glyph">●</span>Immune deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Back pain</p><p class="bulletIndent1"><span class="glyph">●</span>Costovertebral angle tenderness</p><p></p><p>Empiric treatment differs according to whether kidney involvement is suspected.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Likely kidney involvement</strong> – For children with a high likelihood of kidney involvement, we suggest a third-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13125" href="/d/drug information/13125.html" rel="external">cefdinir</a>, <a class="drug drug_pediatric" data-topicid="13127" href="/d/drug information/13127.html" rel="external">cefixime</a>, <a class="drug drug_pediatric" data-topicid="13059" href="/d/drug information/13059.html" rel="external">ceftibuten</a>)  (<a class="graphic graphic_algorithm graphicRef142108" href="/d/graphic/142108.html" rel="external">algorithm 1</a>). The predicted probability of resistance to first-generation cephalosporins, TMP-SMX, and <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> is relatively high [<a href="#rid19">19,35,38,42-45</a>], and the tissue concentrations of <a class="drug drug_pediatric" data-topicid="12645" href="/d/drug information/12645.html" rel="external">nitrofurantoin</a> may not be adequate to eradicate the causative organism.</p><p></p><p class="bulletIndent1">We use one of the following agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13125" href="/d/drug information/13125.html" rel="external">Cefdinir</a> 14 mg/kg by mouth once daily or in two divided doses</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13127" href="/d/drug information/13127.html" rel="external">Cefixime</a> 8 mg/kg by mouth once daily or in two divided doses</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13059" href="/d/drug information/13059.html" rel="external">Ceftibuten</a> 9 mg/kg by mouth once daily</p><p></p><p class="bulletIndent1">Antibiotics are given for 10 days unless urine culture antibiotic susceptibilities demonstrate resistance to the empiric antibiotic chosen. The antibiotic would then need to be changed and treatment with the new antibiotic provided for 10 days. (See <a class="local">'Second-line empiric oral regimens'</a> below.)</p><p></p><p class="bulletIndent1">If the patient has an allergy to cephalosporins or received a cephalosporin in the past two months, start empiric therapy with a second-line empiric antibiotic. (See <a class="local">'Second-line empiric oral regimens'</a> below.)</p><p></p><p class="bulletIndent1">The effectiveness of oral antibiotics for the treatment of febrile patients with UTI has been demonstrated in two randomized trials. In a trial of 306 children 1 to 24 months of age with a febrile UTI, oral therapy with <a class="drug drug_pediatric" data-topicid="13127" href="/d/drug information/13127.html" rel="external">cefixime</a> for 14 days was as effective as intravenous (IV) therapy with <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> for 3 days followed by oral therapy with cefixime [<a href="#rid7">7</a>]. The rates of symptom resolution and sterilization of the urine (100 percent both groups) were the same; differences in the rates of reinfection (4.6 and 7.2 percent) and kidney scarring at 6 months (9.8 and 7.2 percent) were not statistically significant. A similar trial in children 6 months to 16 years diagnosed with pyelonephritis found that the rate of renal scarring among patients treated for 14 days with oral <a class="drug drug_pediatric" data-topicid="13059" href="/d/drug information/13059.html" rel="external">ceftibuten</a> was comparable to those treated with 3 days of IV <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> followed by 11 days of ceftibuten [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unlikely kidney involvement </strong>–<strong> </strong>For children with a low likelihood of kidney involvement, we prefer <a class="drug drug_pediatric" data-topicid="13138" href="/d/drug information/13138.html" rel="external">cephalexin</a> 50 to 100 mg/kg per day by mouth in two divided doses for five days, provided that the local resistance of <em>E. coli </em>to first-generation cephalosporins in the specific community is not high (eg, is not ≥15 percent). If local resistance to cephalosporins is high, one of the second-line antibiotics should be chosen based on local resistance patterns  (<a class="graphic graphic_algorithm graphicRef142108" href="/d/graphic/142108.html" rel="external">algorithm 1</a>). (See <a class="local">'Second-line empiric oral regimens'</a> below.)</p><p></p><p>In a trial of 664 children, aged 2 months to 10 years, with confirmed UTI, those who clinically improved by day 5 of oral antibiotics were randomly assigned to discontinue antibiotics versus complete a 10 day antibiotic course [<a href="#rid46">46</a>]. Treatment failure, defined as a symptomatic UTI on or before a follow-up visit on day 11 through 14, occurred in less than 5 percent of those assigned to short-course therapy and was similar between groups (4.2 versus 0.6 percent).</p><p>Once culture results become available, if the pathogen is resistant to empiric therapy, the authors would change the antibiotic to one to which the pathogen is sensitive. However, other experts would not change therapy if the child was clinically improving [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H1523358600"><span class="h2">Second-line empiric oral regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergy to or recent use of a cephalosporin</strong> –<strong> </strong>In patients with recent use of a cephalosporin or an allergy to cephalosporins, options include TMP-SMX, <a class="drug drug_pediatric" data-topicid="12645" href="/d/drug information/12645.html" rel="external">nitrofurantoin</a>, <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>, and <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>. However, nitrofurantoin should not be used if kidney involvement is likely because its tissue concentration may not be adequate. (See  <a class="medical medical_review" href="/d/html/13535.html" rel="external">"Cephalosporin hypersensitivity: Clinical manifestations and diagnosis", section on 'Immediate versus delayed reactions'</a> and  <a class="medical medical_review" href="/d/html/13535.html" rel="external">"Cephalosporin hypersensitivity: Clinical manifestations and diagnosis", section on 'Challenge procedures'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">Amoxicillin-clavulanate</a> 50 mg/kg per day by mouth (dosed by the <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> component) in two or three divided doses (maximum 500 mg/dose)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TMP-SMX 8 to 12 mg/kg per day of TMP by mouth in two divided doses (maximum 60 to 100 mg every 6 hours)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12645" href="/d/drug information/12645.html" rel="external">Nitrofurantoin</a> 5 to 7 mg/kg per day by mouth divided every 6 hours (50 to 100 mg every 6 hours)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">Ciprofloxacin</a> 10 to 20 mg/kg per dose<strong> </strong>by mouth every 12 hours (maximum 750 mg/dose)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">Ciprofloxacin</a> use should be limited to reduce development of resistance among other bacteria. However, if kidney involvement is suspected, ciprofloxacin is the preferred second-line agent. <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">Amoxicillin-clavulanate</a> and TMP-SMX should be used with caution when kidney involvement is likely because these patients are at risk for renal scarring and resistance rates to these two agents are high.</p><p></p><p>Once culture results become available, if the pathogen is resistant to empiric therapy, the authors would change the antibiotic to one to which the pathogen is sensitive. However, other experts would not change therapy if the child was clinically improving [<a href="#rid47">47</a>].</p><p>Fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>) are effective for <em>E. coli</em>, and resistance in children is rare. However, widespread use of fluoroquinolones is leading to increased resistance among other bacteria [<a href="#rid48">48-50</a>], and ciprofloxacin should not be routinely used as a first-line agent when other options exist [<a href="#rid51">51</a>]. It has been recommended that the use of ciprofloxacin for UTI in children be limited to UTI caused by multidrug-resistant, gram-negative bacteria [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a>.)</p><p class="headingAnchor" id="H3779734943"><span class="h2">Parenteral antibiotics</span><span class="headingEndMark"> — </span>Cephalosporins (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) [<a href="#rid53">53-55</a>] and aminoglycosides (eg, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>) are appropriate first-line parenteral agents for empiric treatment of UTI in children  (<a class="graphic graphic_algorithm graphicRef142108" href="/d/graphic/142108.html" rel="external">algorithm 1</a>). Definitive therapy is based upon the results of urine culture and sensitivities.</p><p>We suggest one of these cephalosporins:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">Cefotaxime</a> (150 mg/kg per day IV divided in three doses)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">Ceftriaxone</a> (50 to 75 mg/kg per day IV; maximum daily dose 2 g)</p><p></p><p>If allergy to cephalosporins exists:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">Gentamicin</a> (7.5 mg/kg per day IV divided in three doses); hydration status and kidney function should be assessed and monitored in patients who are treated with aminoglycosides. Aminoglycoside dosing and monitoring are different in children with impaired kidney function. (See  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p></p><p>The treatment course is usually 10 days [<a href="#rid11">11</a>]. Oral antibiotics can be used to complete the course of therapy for patients who are initially treated with parenteral antibiotics. We generally switch to oral antibiotics when the patient is clinically improved, is tolerating oral fluids, and has been afebrile for 24 hours [<a href="#rid11">11</a>]. There is no minimum duration for parenteral therapy. In retrospective cohort studies in young infants with and without bacteremia, the duration of parenteral antibiotic therapy was not associated with rates of treatment failure or readmission [<a href="#rid56">56-58</a>].</p><p>Once culture results become available, if the pathogen is resistant to empiric therapy, the authors would change the antibiotic to one to which the pathogen is sensitive. However, other experts would not change therapy if the child was clinically improving [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H3829076700"><span class="h1">RESPONSE TO THERAPY</span></p><p class="headingAnchor" id="H3895519363"><span class="h2">Clinical response</span><span class="headingEndMark"> — </span>The clinical condition of most patients improves within 24 to 48 hours of initiation of appropriate antimicrobial therapy [<a href="#rid59">59</a>]. In children whose clinical condition (other than persistent fever) worsens or fails to improve as expected within 48 to 72 hours of initiation of antimicrobial therapy, the patient should be admitted for parenteral therapy. As an example, most of the empiric regimens suggested above do not provide adequate coverage for<em> Enterococcus</em>, and the addition of <a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">ampicillin</a> or <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> may be warranted  (<a class="graphic graphic_algorithm graphicRef142108" href="/d/graphic/142108.html" rel="external">algorithm 1</a>). (See <a class="local">'Determining treatment setting'</a> above and <a class="local">'Parenteral antibiotics'</a> above.)</p><p>Additionally, kidney and bladder ultrasonography should be performed as soon as possible to evaluate for the presence of a kidney abscess [<a href="#rid3">3,60,61</a>]. This is usually performed upon admission. (See <a class="local">'Imaging'</a> below.)</p><p>Although the mean time to resolution of fever is 24 hours, fever may persist beyond 48 hours [<a href="#rid7">7</a>]. In a review of 288 children younger than two years who were admitted to a tertiary-care children's hospital with febrile UTI, 89 percent were afebrile within 48 hours of antimicrobial therapy [<a href="#rid59">59</a>]. No differences were noted between those who remained febrile &gt;48 hours and those who were afebrile within 48 hours with respect to bacteremia (10 and 8 percent, respectively), hydronephrosis (3 and 5 percent, respectively), and significant vesicoureteral reflux (19 and 14 percent, respectively).</p><p class="headingAnchor" id="H3547552438"><span class="h2">Repeat urine culture</span><span class="headingEndMark"> — </span>We do not routinely repeat urine cultures. Several observational studies suggest there is little utility in repeating the urine culture in children with UTI who are treated with an antibiotic to which their uropathogen is susceptible [<a href="#rid59">59,62,63</a>]. Accordingly, it is not necessary to routinely obtain repeat urine cultures during antimicrobial therapy to document sterilization of the urine, provided that the child has had the expected clinical response and the uropathogen is susceptible to the antibiotic that is used for treatment [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H1079867270"><span class="h1">PROPHYLACTIC ANTIBIOTICS</span><span class="headingEndMark"> — </span>The indications for prescribing prophylactic antibiotics are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6066.html" rel="external">"Urinary tract infections in children: Long-term management and prevention", section on 'Antimicrobial prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Antibiotic prophylaxis'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">IMAGING</span></p><p class="headingAnchor" id="H880506880"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>The rationale for imaging in young children with UTI is to identify abnormalities of the genitourinary tract that require additional evaluation or management (eg, obstructive uropathies, dilating vesicoureteral reflux [VUR]). If such abnormalities are detected, steps can be taken to modify the risk of subsequent UTI recurrence and kidney damage (eg, surgical intervention or antibiotic prophylaxis to prevent recurrent UTI).</p><p>The ultimate value of detecting anatomic or functional abnormalities of the urinary tract depends upon the effectiveness of the interventions designed to prevent recurrent UTI and kidney scarring [<a href="#rid66">66,67</a>]. Evidence to support the utility of routine imaging in reducing long-term sequelae (kidney scarring, hypertension, kidney failure) is limited [<a href="#rid68">68-72</a>], and there is a lack of consensus about the optimal imaging strategy [<a href="#rid3">3,64,73-75</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Ultrasonography</span><span class="headingEndMark"> — </span>Kidney and bladder ultrasonography (KBUS) is a noninvasive test that can demonstrate the size and shape of the kidneys, the presence of duplication and dilatation of the ureters, and the existence of gross anatomic abnormalities. KBUS can also identify kidney or perirenal abscess or pyonephrosis in children with acute UTI who fail to improve with antimicrobial therapy. Although KBUS is not reliable in diagnosing kidney scarring or VUR [<a href="#rid76">76-79</a>], abnormalities on KBUS after first UTI are useful in predicting the risk of kidney scarring or VUR [<a href="#rid72">72,80</a>]. (See  <a class="medical medical_review" href="/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"</a>.)</p><p>KBUS is estimated to yield management-altering abnormalities (ie, requiring additional evaluation or surgery) in 1 to 3 percent of cases of first febrile UTI in young children 2 to 24 months of age [<a href="#rid1">1,3,81-84</a>]. The false positive rate is between 2 and 3 percent [<a href="#rid3">3</a>]. The major advantages of KBUS are the lack of exposure to radiation and helpfulness in predicting risk of kidney scarring [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H35041432"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Given the potentially large benefit of detecting malformations in a small number of children and the low risk of harm, we suggest KBUS for the following children:</p><p class="bulletIndent1"><span class="glyph">●</span>Children younger than two years of age with a first febrile UTI</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children of any age with recurrent febrile UTIs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children of any age with a UTI who have a family history of kidney or urologic disease, poor growth, or hypertension  (<a class="graphic graphic_table graphicRef63856 graphicRef52646" href="/d/graphic/63856.html" rel="external">table 1A-B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children who do not respond as expected to appropriate antimicrobial therapy</p><p></p><p>However, prenatal ultrasonography is often performed after 30 to 32 weeks of gestation – a time at which the urinary tract is fully developed; we may elect not to perform KBUS (in children of any age) if prenatal ultrasonography that was performed at a reputable center was normal and the study results are accessible [<a href="#rid85">85,86</a>].</p><p>The American Academy of Pediatrics (AAP) recommends KBUS for all infants and children 2 to 24 months following their first febrile UTI [<a href="#rid3">3,11</a>]. The United Kingdom's National Institute for Health and Care Excellence (NICE) guidelines on UTI in children recommend KBUS for infants younger than six months and for children older than six months who have atypical or recurrent UTI [<a href="#rid64">64</a>]. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass, elevated creatinine, septicemia, infection with an organism other than <em>E. coli</em>, and failure to respond to antibiotics within 48 hours; they define recurrence as ≥2 episodes of upper UTI, 1 episode of upper UTI plus ≥1 episode of lower UTI, or ≥3 episodes of lower UTI.</p><p class="headingAnchor" id="H973874071"><span class="h3">Timing</span><span class="headingEndMark"> — </span>When the KBUS should be performed depends upon the clinical situation [<a href="#rid3">3</a>]. In infants and young children with unusually severe illness or failure to improve as expected after initiation of antimicrobial therapy, KBUS should be performed as soon as possible during the acute phase of illness to identify complications (eg, kidney or perirenal abscess, pyonephrosis). However, for infants and young children who respond as expected to appropriate antimicrobial therapy, KBUS should be performed after the acute phase (to reduce the risk of false positive results secondary to kidney inflammation during the acute episode) [<a href="#rid3">3,64</a>]. The decision to treat with prophylactic antibiotics pending results of imaging is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6066.html" rel="external">"Urinary tract infections in children: Long-term management and prevention", section on 'Antimicrobial prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Antibiotic prophylaxis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Voiding cystourethrogram</span><span class="headingEndMark"> — </span>The voiding cystourethrogram (VCUG) is the test of choice to establish the presence and degree of VUR. VUR is the retrograde passage of urine from the bladder into the upper urinary tract. It is an important risk factor for kidney scarring. Approximately 25 to 30 percent of children (0 to 18 years) with a first UTI have VUR [<a href="#rid67">67,72</a>]. (See <a class="local">'Prognosis'</a> below and  <a class="medical medical_review" href="/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"</a> and  <a class="medical medical_review" href="/d/html/5988.html" rel="external">"Urinary tract infections in children: Epidemiology and risk factors", section on 'Risk factors for renal scarring'</a>.)</p><p>VCUG involves catheterization to fill the bladder with a radiopaque or radioactive liquid and recording of VUR during voiding. VCUG is expensive, invasive, and may miss a significant portion of children who are at risk for kidney scarring [<a href="#rid67">67</a>]. The radiation exposure depends upon the technique and equipment used (the pediatric effective dose estimate ranges from 0.03 to 0.3 millisieverts) [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a> and  <a class="medical medical_review" href="/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H95675897"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Decisions about performing a VCUG in infants and children with UTI must take into consideration the likelihood of VUR, severity of UTI, the importance placed on preventing recurrences, the cost and discomfort of the VCUG, and perceived likelihood of adherence to prophylaxis (if indicated).</p><p>Pending results of ongoing cost-effectiveness analysis of the Randomized Intervention for Vesicoureteral Reflux (RIVUR) data, we suggest performance of a VCUG to diagnose VUR in:</p><p class="bulletIndent1"><span class="glyph">●</span>Children of any age with two or more febrile UTIs, <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children of any age with a first febrile UTI <strong>and</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any anomalies on kidney ultrasound, <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The combination of temperature ≥39°C (102.2°F) and a pathogen other than <em>E. coli</em>, <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor growth or hypertension  (<a class="graphic graphic_table graphicRef63856 graphicRef52646" href="/d/graphic/63856.html" rel="external">table 1A-B</a>)</p><p></p><p>In a meta-analysis of individual patient data from nine studies including 1280 children (0 to 18 years) with initial UTI, 68 percent of children with Grade IV or V VUR had either abnormal KBUS or the combination of temperature ≥39°C (102.2°F) and a pathogen other than <em>E. coli</em> [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"</a> and  <a class="medical medical_review" href="/d/html/6095.html" rel="external">"Management of vesicoureteral reflux"</a>.)</p><p>For children with a first febrile UTI and <strong>without</strong> 1) abnormalities on kidney ultrasonography, 2) the combination of temperature ≥39°C (102.2°F) and a pathogen other than <em>E. coli</em>, 3) poor growth, or 4) hypertension, a strategy of "watchful waiting" (ie, observation and performance of VCUG with recurrence) seems reasonable [<a href="#rid88">88</a>], particularly if the caregivers would prefer to avoid prophylactic antibiotics. These children are less likely to have VUR and VCUG results likely to affect management.</p><p>It remains uncertain whether the benefits of detection and treatment of VUR after the first UTI outweigh the risks. The uncertainty centers on the changing view of the role of VUR in the development of kidney damage and progressive kidney disease and the lack of clarity regarding the effectiveness of medical or surgical management of VUR in reducing the risk of kidney scarring [<a href="#rid67">67</a>]. Although the risk of kidney scarring is increased in children with VUR compared with children without VUR (41 versus 17 percent in a systematic review) and increases with increasing grades of VUR, VUR is neither necessary nor sufficient for the development of kidney scars [<a href="#rid67">67,72</a>]. (See  <a class="medical medical_review" href="/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux", section on 'Loss of renal parenchyma'</a>.)</p><p>Early trials comparing antireflux surgery with antimicrobial prophylaxis in children with VUR showed no differences in rates of recurrent UTI or kidney scarring [<a href="#rid89">89-92</a>], but the lack of a placebo or observation group precluded determination that either treatment was more effective than no treatment [<a href="#rid89">89-92</a>]. Subsequent randomized trials comparing antimicrobial prophylaxis with no treatment or placebo had inconsistent results regarding recurrence of UTI, but most of these trials were not blinded [<a href="#rid81">81,93-97</a>].</p><p>The RIVUR trial addressed many of these issues. It evaluated the efficacy of <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) prophylaxis in preventing febrile or symptomatic UTI recurrences (primary outcome) in 607 children (two months to six years) who were diagnosed with Grade I to IV VUR after a first or second febrile or symptomatic UTI and were followed for two years [<a href="#rid28">28</a>]. Kidney scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial resistance were secondary outcomes. The RIVUR trial demonstrated unequivocally that prophylactic antibiotics decrease the risk of febrile, recurrent UTI (hazard ratio 0.50, 95% CI 0.34-0.74) [<a href="#rid28">28</a>]. Nearly twice as many children receiving placebo than children receiving prophylaxis were categorized as treatment failures (defined by two febrile UTIs, one febrile UTI and three symptomatic UTIs, four symptomatic UTIs, or new or worsening kidney scarring). However, antibiotic prophylaxis did not reduce the risk of scarring and was associated with antimicrobial resistance. (See <a class="local">'Prophylactic antibiotics'</a> above.)</p><p>The 2011 AAP clinical practice guidelines (reaffirmed in 2016) recommend postponing VCUG until the second febrile UTI in children 2 to 24 months of age unless there are atypical or complex clinical circumstances or the KBUS reveals hydronephrosis, scarring, or other findings suggestive of high-grade (IV or V) VUR or obstructive uropathy [<a href="#rid3">3,11</a>]. The recommendation was reaffirmed after publication of the results of the RIVUR trial [<a href="#rid98">98</a>]. According to the guidelines, the benefit of avoiding radiation exposure and discomfort in the majority of patients outweighs delayed detection of a small number of cases of high-grade reflux or surgically correctible abnormalities. However, the guidelines acknowledge that caregiver preferences may play a role in the decision to perform VCUG.</p><p>The United Kingdom's NICE guidelines suggest VCUG for infants &lt;6 months with atypical or recurrent UTI [<a href="#rid64">64</a>]. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass, elevated creatinine, septicemia, infection with an organism other than <em>E. coli</em>, and failure to respond to antibiotics within 48 hours; they define recurrence as ≥2 episodes of upper UTI, one episode of upper UTI plus ≥1 episode of lower UTI, or ≥3 episodes of lower UTI. The NICE guidelines also suggest that VCUG may be warranted for children six months to three years with atypical or recurrent UTI and dilation on ultrasonography, poor urine flow, non-<em>E. coli</em> infection, or family history of VUR.</p><p class="headingAnchor" id="H973874079"><span class="h3">Timing</span><span class="headingEndMark"> — </span>Although VCUG is often scheduled several weeks after UTI, it may be performed as soon as the patient is asymptomatic [<a href="#rid99">99</a>]. Early imaging (as early as the first week) does not appear to falsely increase the detection of VUR [<a href="#rid100">100</a>]. To avoid the use of prophylactic antibiotics in children without VUR, we prefer to conduct VCUGs during the last days of antimicrobial therapy or immediately after completion of antimicrobial therapy for UTI.</p><p class="headingAnchor" id="H19"><span class="h2">Kidney scintigraphy</span><span class="headingEndMark"> — </span>Kidney scintigraphy using <a class="drug drug_pediatric" data-topicid="138539" href="/d/drug information/138539.html" rel="external">technetium Tc-99m succimer</a> (dimercaptosuccinic acid [DMSA]) can be used to detect acute pyelonephritis and kidney scarring in the acute and chronic settings, respectively [<a href="#rid1">1,3,101</a>]. DMSA is injected intravenously, and uptake by the kidney is measured two to four hours later. Areas of decreased uptake represent pyelonephritis or scarring. DMSA scans are expensive, invasive, and expose children to radiation (the pediatric effective dose estimate ranges from 0.3 to 3 millisieverts) [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p>The role of kidney scintigraphy in the management of children with acute UTI is controversial. Scintigraphy at the time of an acute UTI provides information about the extent of kidney parenchymal involvement. In addition, DMSA will identify most (&gt;70 percent) children with moderate to severe VUR (Grade III or higher) [<a href="#rid78">78,102-104</a>]. This observation has prompted some experts to suggest that DMSA be used as the initial imaging test to identify children at higher risk for kidney scarring (the "top down" approach) [<a href="#rid105">105</a>].</p><p>However, using DMSA as the initial test to identify high-risk children is more expensive and involves exposure to radiation [<a href="#rid106">106</a>]. Furthermore, since most young febrile children with UTI have pyelonephritis and a positive DMSA, this strategy may lead to identification of a large number of children who may or may not be at risk for future UTI [<a href="#rid1">1,67</a>]. In a systematic review of 33 studies, approximately 60 percent of children with initial UTI had DMSA scans consistent with acute pyelonephritis in the acute phase of illness, but only 15 percent had kidney scarring at follow-up [<a href="#rid67">67</a>]. It is unclear how to best manage children with positive acute-phase DMSA scan. Careful clinical follow-up of all children with UTI may obviate the need for routine DMSA. (See <a class="local">'Follow-up'</a> below.)</p><p>We suggest not using DMSA in the routine evaluation of children with first UTI. This is consistent with the AAP and NICE guidelines [<a href="#rid3">3,11,64</a>].</p><p>Some experts recommend DMSA 6 to 12 months after acute infection to detect the formation of scarring which would require follow-up [<a href="#rid107">107,108</a>]. The NICE guidelines recommend DMSA four to six months after acute infection for children younger than three years with atypical or recurrent UTI and for children older than three years with recurrent UTI [<a href="#rid64">64</a>]. They define atypical UTI as serious illness, poor urine flow, abdominal or bladder mass, elevated creatinine, septicemia, infection with an organism other than <em>E. coli</em>, and failure to respond to antibiotics within 48 hours; they define recurrence as ≥2 episodes of upper UTI, one episode of upper UTI plus ≥1 episode of lower UTI, or ≥3 episodes of lower UTI.</p><p class="headingAnchor" id="H522687481"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Caregivers of infants and young children who have been treated for a febrile UTI and children with bowel and bladder dysfunction (a risk factor for recurrent UTI) should be instructed to seek prompt evaluation for subsequent febrile illnesses to ensure prompt recognition and treatment of recurrent UTI [<a href="#rid3">3,64,97</a>]. The evaluation of these episodes should include urinalysis and urine culture [<a href="#rid1">1</a>].</p><p>Recurrent UTI is a risk factor for kidney scarring, and the risk of kidney scarring is substantially increased with the second febrile UTI [<a href="#rid109">109</a>]. Identification of children at risk for recurrent febrile UTI and treatment of bowel and bladder dysfunction that predisposes many children to UTI may be more important than identifying anatomic or functional genitourinary abnormalities after the first febrile UTI in preventing kidney scarring [<a href="#rid3">3,109</a>].</p><p>In post-hoc analysis of two multicenter prospective studies including 345 children age 2 to 71 months with a history of UTI who did not have vesicoureteral reflux and did not receive prophylactic antibiotics, 14.2 percent had ≥2 febrile UTIs [<a href="#rid109">109</a>]. The incidence of kidney scarring was 2.8 percent after the first febrile UTI, 26 percent after two febrile UTIs, and 29 percent after three febrile UTIs. Compared with a single febrile UTI, the odds of kidney scarring were 11.8 times greater (95% CI 4.1-34.4 times) after two febrile UTIs and 13.7 times greater (95% CI 3.4-54.4 times) after ≥3 febrile UTIs, highlighting the importance of identifying children at increased risk for a second febrile UTI.</p><p>Primary care follow-up for infants and young children who have had a febrile UTI should include regular monitoring of height, weight, and blood pressure. (See  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H880507219"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Indications for referral to a nephrologist or urologist with expertise in children include [<a href="#rid64">64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent UTI</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilating vesicoureteral reflux (Grades III to V) or any other congenital kidney abnormality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other kidney abnormalities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired kidney function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated blood pressure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bowel and bladder dysfunction refractory to primary care measures (see  <a class="medical medical_review" href="/d/html/6066.html" rel="external">"Urinary tract infections in children: Long-term management and prevention", section on 'Identify and treat bowel and bladder dysfunction'</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The short-term outcome of first UTI in children (&lt;19 years) was described in a systematic review of 33 studies, including 4891 children [<a href="#rid67">67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-five percent had vesicoureteral reflux (VUR); 2.5 percent had Grade IV or V VUR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VUR was associated with an increased risk of developing acute pyelonephritis (relative risk [RR] 1.5, 95% CI 1.1-1.9) and kidney scarring (RR 2.6, 95% CI 1.7-3.9); Grade III or higher VUR was associated with increased risk of kidney scarring compared with lower grades (RR 2.1, 95% CI 1.4-3.2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fifteen percent (95% CI 11-18 percent) of children had evidence of kidney scarring on follow-up dimercaptosuccinic acid (DMSA) scan (5 to 24 months later); the long-term significance of scarring, as identified by DMSA, remains to be determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eight percent (95% CI 5-11 percent) of children had at least one recurrence.</p><p></p><p>Recurrence among children younger than six years was more likely among White children (hazard ratio [HR] 2.0), those age three to five years (HR approximately 2.5), and those with Grade IV to V VUR (HR 4.38) [<a href="#rid25">25</a>].</p><p>Predicting which children with UTI will develop long-term sequelae remains difficult. A systematic review of the literature found only four prospective, relatively small studies addressing this question [<a href="#rid110">110</a>]. The large majority of children with UTI have no long-term sequelae, as illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 111 high-risk females who were followed for 6 to 32 years after their initial UTI, only 7 (6 percent) had decreased glomerular filtration rate (GFR), and none developed end-stage kidney disease [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 68 children with history of urographic kidney scarring who were followed for 16 to 26 years after their index UTI, median GFR [<a href="#rid68">68</a>] and mean 24-hour ambulatory blood pressure [<a href="#rid112">112</a>] were no different in children with and without urographic kidney scarring. No child developed end-stage kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 226 children with UTI followed for 1 to 41 years, 2 developed chronic kidney disease that appeared to be attributable to the UTIs [<a href="#rid113">113</a>].</p><p></p><p>The prognosis for children with nonfebrile UTI is discussed separately. (See  <a class="medical medical_review" href="/d/html/93961.html" rel="external">"Acute infectious cystitis: Management and prognosis in children older than two years and adolescents", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H327788904"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109483.html" rel="external">"Society guideline links: Urinary tract infections in children"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16963.html" rel="external">"Patient education: Urinary tract infections in children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/1171.html" rel="external">"Patient education: Urinary tract infections in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision to hospitalize</strong> – Most children with urinary tract infection (UTI) can be managed as outpatients. Indications for hospitalization include age &lt;2 months, clinical urosepsis, febrile immunocompromised patient, vomiting or inability to tolerate oral medication, lack of reliable outpatient follow-up, and failure to respond to outpatient therapy. (See <a class="local">'Determining treatment setting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric oral antimicrobial therapy</strong> – Following appropriate urine collection, immediate initiation of empiric antimicrobial therapy is warranted in children with a high probability of UTI based on available clinical and laboratory data  (<a class="graphic graphic_algorithm graphicRef142108" href="/d/graphic/142108.html" rel="external">algorithm 1</a>). This is particularly true for young children with any features that suggest likely kidney involvement, including (see <a class="local">'Determining need for early empiric antibiotic therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever (especially if ≥39°C [102.2°F] or &gt;48 hours)</p><p class="bulletIndent2"><span class="glyph">•</span>Ill appearance</p><p class="bulletIndent2"><span class="glyph">•</span>Costovertebral angle tenderness</p><p class="bulletIndent2"><span class="glyph">•</span>Known immune deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>Known urologic abnormality (eg, Grade IV or V vesicoureteral reflux [VUR])</p><p></p><p class="bulletIndent1">In children with suspected UTI, we suggest a cephalosporin as the first-line oral agent rather than other antibiotics such as <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> or <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Cephalosporins are effective against <em>Escherichia coli</em>, which is the most common pathogen. The agent of choice should be guided by local resistance patterns. (See <a class="local">'Preferred empiric oral regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with likely kidney involvement, we use a third-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13125" href="/d/drug information/13125.html" rel="external">cefdinir</a>, <a class="drug drug_pediatric" data-topicid="13127" href="/d/drug information/13127.html" rel="external">cefixime</a>, <a class="drug drug_pediatric" data-topicid="13059" href="/d/drug information/13059.html" rel="external">ceftibuten</a>) and treat for 10 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with unlikely kidney involvement, we prefer a 5-day course of a first-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13138" href="/d/drug information/13138.html" rel="external">cephalexin</a>) provided that the local resistance of <em>E. coli </em>to first-generation cephalosporins is not increased.</p><p></p><p class="bulletIndent1">In patients with recent use of a cephalosporin or a cephalosporin allergy, alternatives include TMP-SMX, <a class="drug drug_pediatric" data-topicid="12645" href="/d/drug information/12645.html" rel="external">nitrofurantoin</a>, <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>, or <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> with the following exceptions: Nitrofurantoin should not be used if kidney involvement is likely because tissue concentrations may not be adequate to eradicate the causative organism, and ciprofloxacin use should be limited to reduce development of resistance among other bacteria. (See <a class="local">'Second-line empiric oral regimens'</a> above.)</p><p></p><p class="bulletIndent1">Definitive therapy is based upon the results of urine culture and sensitivities. (See <a class="local">'Choice of antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric parenteral antimicrobial therapy (hospitalized patients)</strong> – In children with suspected UTI who require parenteral antibiotics, we suggest a third-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>) rather than a first generation cephalosporin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Parenteral antibiotics'</a> above.)</p><p></p><p>In patients with recent use of a cephalosporin or cephalosporin allergy, an aminoglycoside, such as <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, is an alternative.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – The clinical condition of most patients improves within 24 to 48 hours of initiation of appropriate antimicrobial therapy. (See <a class="local">'Clinical response'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children whose clinical condition worsens or fails to improve as expected within 48 to 72 hours of initiation of antimicrobial therapy should be admitted to the hospital for parenteral therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney bladder ultrasonography (KBUS) should be performed as soon as possible following hospital admission to evaluate for the presence of a renal abscess.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>KBUS – We obtain routine KBUS after first febrile UTI in children younger than two years who did not have normal prenatal ultrasonography at a reputable center at &gt;30 to 32 weeks of gestation. We also obtain KBUS for children of any age with recurrent febrile UTIs and children of any age with a first UTI who have poor growth, hypertension, or a family history of kidney or urologic disease. (See <a class="local">'Ultrasonography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VCUG – We obtain voiding cystourethrogram (VCUG) to diagnose VUR in children of any age with ≥2 febrile UTIs. We also obtain VCUG in children of any age with a first febrile UTI <strong>and:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Any anomalies on kidney ultrasound, <strong>or</strong></p><p class="bulletIndent3"><span class="glyph">-</span>The combination of temperature ≥39°C (102.2°F) and a pathogen other than <em>E. coli</em>, <strong>or</strong></p><p class="bulletIndent3"><span class="glyph">-</span>Poor growth or hypertension. (See <a class="local">'Voiding cystourethrogram'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The majority of children with UTI have no long-term sequelae. Prediction of long-term sequelae in children with UTI remains difficult. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348:195.</a></li><li><a class="nounderline abstract_t">Larcombe J. Urinary tract infection in children. Clin Evid 2005; :429.</a></li><li><a class="nounderline abstract_t">Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 2011; 128:595.</a></li><li><a class="nounderline abstract_t">Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895.</a></li><li><a class="nounderline abstract_t">Shaikh N, Hoberman A, Hum SW, et al. Development and Validation of a Calculator for Estimating the Probability of Urinary Tract Infection in Young Febrile Children. JAMA Pediatr 2018; 172:550.</a></li><li><a class="nounderline abstract_t">Shaikh N, Mattoo TK, Keren R, et al. Early Antibiotic Treatment for Pediatric Febrile Urinary Tract Infection and Renal Scarring. JAMA Pediatr 2016; 170:848.</a></li><li><a class="nounderline abstract_t">Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999; 104:79.</a></li><li><a class="nounderline abstract_t">Strohmeier Y, Hodson EM, Willis NS, et al. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2014; :CD003772.</a></li><li><a class="nounderline abstract_t">Hom J. Are oral antibiotics equivalent to intravenous antibiotics for the initial management of pyelonephritis in children? Paediatr Child Health 2010; 15:150.</a></li><li><a class="nounderline abstract_t">Chaudhari PP, Monuteaux MC, Bachur RG. Emergency Department Revisits After an Initial Parenteral Antibiotic Dose for UTI. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">SUBCOMMITTEE ON URINARY TRACT INFECTION. Reaffirmation of AAP Clinical Practice Guideline: The Diagnosis and Management of the Initial Urinary Tract Infection in Febrile Infants and Young Children 2-24 Months of Age. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Montini G, Toffolo A, Zucchetta P, et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ 2007; 335:386.</a></li><li><a class="nounderline abstract_t">Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006; 53:379.</a></li><li><a class="nounderline abstract_t">Schnadower D, Kuppermann N, Macias CG, et al. Outpatient management of young febrile infants with urinary tract infections. Pediatr Emerg Care 2014; 30:591.</a></li><li class="breakAll">European Association of Urology Guidelines. Paediatric Urology. Urinary tract infections in children. Available at: https://uroweb.org/guideline/paediatric-urology/#3_8 (Accessed on September 03, 2019).</li><li><a class="nounderline abstract_t">Sarvis AB, Sarvis RC, Schnadower D, et al. Admit Versus Discharge-A Cost Analysis of Infants 29 to 60 Days Old With Febrile Urinary Tract Infection at Low Risk for Bacteremia. Acad Pediatr 2019; 19:209.</a></li><li><a class="nounderline abstract_t">Schnadower D, Kuppermann N, Macias CG, et al. Febrile infants with urinary tract infections at very low risk for adverse events and bacteremia. Pediatrics 2010; 126:1074.</a></li><li><a class="nounderline abstract_t">Shaikh N, Hoberman A, Keren R, et al. Predictors of Antimicrobial Resistance among Pathogens Causing Urinary Tract Infection in Children. J Pediatr 2016; 171:116.</a></li><li><a class="nounderline abstract_t">Bryce A, Hay AD, Lane IF, et al. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ 2016; 352:i939.</a></li><li><a class="nounderline abstract_t">Nelson CP, Hoberman A, Shaikh N, et al. Antimicrobial Resistance and Urinary Tract Infection Recurrence. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Selekman RE, Shapiro DJ, Boscardin J, et al. Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Lutter SA, Currie ML, Mitz LB, Greenbaum LA. Antibiotic resistance patterns in children hospitalized for urinary tract infections. Arch Pediatr Adolesc Med 2005; 159:924.</a></li><li><a class="nounderline abstract_t">Cheng CH, Tsai MH, Huang YC, et al. Antibiotic resistance patterns of community-acquired urinary tract infections in children with vesicoureteral reflux receiving prophylactic antibiotic therapy. Pediatrics 2008; 122:1212.</a></li><li><a class="nounderline abstract_t">Dayan N, Dabbah H, Weissman I, et al. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr 2013; 163:1417.</a></li><li><a class="nounderline abstract_t">Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 2007; 298:179.</a></li><li><a class="nounderline abstract_t">Paschke AA, Zaoutis T, Conway PH, et al. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics 2010; 125:664.</a></li><li><a class="nounderline abstract_t">Bitsori M, Maraki S, Galanakis E. Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis. Pediatr Nephrol 2014; 29:1053.</a></li><li><a class="nounderline abstract_t">RIVUR Trial Investigators, Hoberman A, Greenfield SP, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 2014; 370:2367.</a></li><li><a class="nounderline abstract_t">Neuhaus TJ, Berger C, Buechner K, et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. Eur J Pediatr 2008; 167:1037.</a></li><li><a class="nounderline abstract_t">Bonsu BK, Shuler L, Sawicki L, et al. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections. Acad Emerg Med 2006; 13:76.</a></li><li><a class="nounderline abstract_t">Yakubov R, van den Akker M, Machamad K, et al. Antimicrobial Resistance Among Uropathogens That Cause Childhood Community-acquired Urinary Tract Infections in Central Israel. Pediatr Infect Dis J 2017; 36:113.</a></li><li><a class="nounderline abstract_t">Ladhani S, Gransden W. Increasing antibiotic resistance among urinary tract isolates. Arch Dis Child 2003; 88:444.</a></li><li><a class="nounderline abstract_t">Allen UD, MacDonald N, Fuite L, et al. Risk factors for resistance to "first-line" antimicrobials among urinary tract isolates of Escherichia coli in children. CMAJ 1999; 160:1436.</a></li><li><a class="nounderline abstract_t">Ismaili K, Wissing KM, Lolin K, et al. Characteristics of first urinary tract infection with fever in children: a prospective clinical and imaging study. Pediatr Infect Dis J 2011; 30:371.</a></li><li><a class="nounderline abstract_t">Tamma PD, Sklansky DJ, Palazzi DL, et al. Antibiotic susceptibility of common pediatric uropathogens in the United States. Clin Infect Dis 2014; 59:750.</a></li><li><a class="nounderline abstract_t">Bryce A, Costelloe C, Wootton M, et al. Comparison of risk factors for, and prevalence of, antibiotic resistance in contaminating and pathogenic urinary Escherichia coli in children in primary care: prospective cohort study. J Antimicrob Chemother 2018; 73:1359.</a></li><li><a class="nounderline abstract_t">Degnan LA, Milstone AM, Diener-West M, Lee CK. Extended-Spectrum Beta-Lactamase Bacteria From Urine Isolates in Children. J Pediatr Pharmacol Ther 2015; 20:373.</a></li><li><a class="nounderline abstract_t">Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol 2013; 190:222.</a></li><li><a class="nounderline abstract_t">Goldraich NP, Manfroi A. Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials. Pediatr Nephrol 2002; 17:173.</a></li><li><a class="nounderline abstract_t">McLoughlin TG Jr, Joseph MM. Antibiotic resistance patterns of uropathogens in pediatric emergency department patients. Acad Emerg Med 2003; 10:347.</a></li><li><a class="nounderline abstract_t">Prais D, Straussberg R, Avitzur Y, et al. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child 2003; 88:215.</a></li><li><a class="nounderline abstract_t">Swerkersson S, Jodal U, Åhrén C, Hansson S. Urinary tract infection in small outpatient children: the influence of age and gender on resistance to oral antimicrobials. Eur J Pediatr 2014; 173:1075.</a></li><li><a class="nounderline abstract_t">Alberici I, Bayazit AK, Drozdz D, et al. Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group. Eur J Pediatr 2015; 174:783.</a></li><li><a class="nounderline abstract_t">Raman G, McMullan B, Taylor P, et al. Multiresistant E. coli urine infections in children: a case-control study. Arch Dis Child 2018; 103:336.</a></li><li><a class="nounderline abstract_t">Hain G, Goldbart A, Sagi O, Ben-Shimol S. High Rates of Antibiotic Nonsusceptibility in Gram-negative Urinary Tract Infection in Children With Risk Factors Occurring in the Preceding Month: Considerations for Choosing Empiric Treatment. Pediatr Infect Dis J 2021; 40:639.</a></li><li><a class="nounderline abstract_t">Zaoutis T, Shaikh N, Fisher BT, et al. Short-Course Therapy for Urinary Tract Infections in Children: The SCOUT Randomized Clinical Trial. JAMA Pediatr 2023; 177:782.</a></li><li><a class="nounderline abstract_t">Wang ME, Lee V, Greenhow TL, et al. Clinical Response to Discordant Therapy in Third-Generation Cephalosporin-Resistant UTIs. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Pickering LK. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 2004; 15:71.</a></li><li><a class="nounderline abstract_t">McNeeley DF, Eckert SJ, Noel GJ. Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children. Pediatr Infect Dis J 2000; 19:675.</a></li><li><a class="nounderline abstract_t">Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37:1643.</a></li><li class="breakAll">United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm (Accessed on July 28, 2016).</li><li><a class="nounderline abstract_t">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005; 18:417.</a></li><li><a class="nounderline abstract_t">Arrieta AC, Bradley JS. Empiric use of cefepime in the treatment of serious urinary tract infections in children. Pediatr Infect Dis J 2001; 20:350.</a></li><li><a class="nounderline abstract_t">Jones ME, Karlowsky JA, Draghi DC, et al. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. Eur J Clin Microbiol Infect Dis 2004; 23:445.</a></li><li><a class="nounderline abstract_t">Brady PW, Conway PH, Goudie A. Length of intravenous antibiotic therapy and treatment failure in infants with urinary tract infections. Pediatrics 2010; 126:196.</a></li><li><a class="nounderline abstract_t">Lewis-de Los Angeles WW, Thurm C, Hersh AL, et al. Trends in Intravenous Antibiotic Duration for Urinary Tract Infections in Young Infants. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Desai S, Aronson PL, Shabanova V, et al. Parenteral Antibiotic Therapy Duration in Young Infants With Bacteremic Urinary Tract Infections. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Bachur R. Nonresponders: prolonged fever among infants with urinary tract infections. Pediatrics 2000; 105:E59.</a></li><li><a class="nounderline abstract_t">Dacher JN, Hitzel A, Avni FE, Vera P. Imaging strategies in pediatric urinary tract infection. Eur Radiol 2005; 15:1283.</a></li><li><a class="nounderline abstract_t">Cheng CH, Tsai MH, Su LH, et al. Renal abscess in children: a 10-year clinical and radiologic experience in a tertiary medical center. Pediatr Infect Dis J 2008; 27:1025.</a></li><li><a class="nounderline abstract_t">Oreskovic NM, Sembrano EU. Repeat urine cultures in children who are admitted with urinary tract infections. Pediatrics 2007; 119:e325.</a></li><li><a class="nounderline abstract_t">Currie ML, Mitz L, Raasch CS, Greenbaum LA. Follow-up urine cultures and fever in children with urinary tract infection. Arch Pediatr Adolesc Med 2003; 157:1237.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Urinary tract infection in children. August 2007. Available at: www.nice.org.uk/CG54 (Accessed on September 07, 2011).</li><li class="breakAll">Choosing Wisely. American Academy of Pediatrics – Section on Nephrology and the American Society of Pediatric Nephrology. Available at: http://www.choosingwisely.org/clinician-lists/aap-aspn-follow-up-urine-cultures-after-treatment-for-uncomplicated-uti/ (Accessed on September 11, 2018).</li><li><a class="nounderline abstract_t">Keren R. Imaging and treatment strategies for children after first urinary tract infection. Curr Opin Pediatr 2007; 19:705.</a></li><li><a class="nounderline abstract_t">Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics 2010; 126:1084.</a></li><li><a class="nounderline abstract_t">Wennerström M, Hansson S, Jodal U, et al. Renal function 16 to 26 years after the first urinary tract infection in childhood. Arch Pediatr Adolesc Med 2000; 154:339.</a></li><li><a class="nounderline abstract_t">Verrier Jones K. Time to review the value of imaging after urinary tract infection in infants. Arch Dis Child 2005; 90:663.</a></li><li><a class="nounderline abstract_t">Moorthy I, Easty M, McHugh K, et al. The presence of vesicoureteric reflux does not identify a population at risk for renal scarring following a first urinary tract infection. Arch Dis Child 2005; 90:733.</a></li><li><a class="nounderline abstract_t">Westwood ME, Whiting PF, Cooper J, et al. Further investigation of confirmed urinary tract infection (UTI) in children under five years: a systematic review. BMC Pediatr 2005; 5:2.</a></li><li><a class="nounderline abstract_t">Shaikh N, Craig JC, Rovers MM, et al. Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr 2014; 168:893.</a></li><li><a class="nounderline abstract_t">Wan J, Skoog SJ, Hulbert WC, et al. Section on Urology response to new Guidelines for the diagnosis and management of UTI. Pediatrics 2012; 129:e1051.</a></li><li><a class="nounderline abstract_t">Roberts KB, Finnell SM, Downs SM. Response to the AAP Section on Urology concerns about the AAP Urinary Tract Infection Guideline. Pediatrics 2012; 129:e1054.</a></li><li><a class="nounderline abstract_t">La Scola C, De Mutiis C, Hewitt IK, et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics 2013; 131:e665.</a></li><li><a class="nounderline abstract_t">Massanyi EZ, Preece J, Gupta A, et al. Utility of screening ultrasound after first febrile UTI among patients with clinically significant vesicoureteral reflux. Urology 2013; 82:905.</a></li><li><a class="nounderline abstract_t">Nelson CP, Johnson EK, Logvinenko T, Chow JS. Ultrasound as a screening test for genitourinary anomalies in children with UTI. Pediatrics 2014; 133:e394.</a></li><li><a class="nounderline abstract_t">Shaikh N, Spingarn RB, Hum SW. Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections. Cochrane Database Syst Rev 2016; 7:CD010657.</a></li><li><a class="nounderline abstract_t">Finkelstein JB, Rague JT, Chow J, et al. Accuracy of Ultrasound in Identifying Renal Scarring as Compared to DMSA Scan. Urology 2020; 138:134.</a></li><li><a class="nounderline abstract_t">Mohammad D, Farooqi A, Mattoo TK. Kidney Echogenicity and Vesicoureteral Reflux in Children with Febrile Urinary Tract Infection. J Pediatr 2022; 242:201.</a></li><li><a class="nounderline abstract_t">Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics 2008; 122:1064.</a></li><li><a class="nounderline abstract_t">Friedman S, Reif S, Assia A, et al. Clinical and laboratory characteristics of non-E. coli urinary tract infections. Arch Dis Child 2006; 91:845.</a></li><li><a class="nounderline abstract_t">Alon US, Ganapathy S. Should renal ultrasonography be done routinely in children with first urinary tract infection? Clin Pediatr (Phila) 1999; 38:21.</a></li><li><a class="nounderline abstract_t">Yang S, Gill PJ, Anwar MR, et al. Kidney Ultrasonography After First Febrile Urinary Tract Infection in Children: A Systematic Review and Meta-analysis. JAMA Pediatr 2023; 177:764.</a></li><li><a class="nounderline abstract_t">Chitty LS, Hunt GH, Moore J, Lobb MO. Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population. BMJ 1991; 303:1165.</a></li><li><a class="nounderline abstract_t">Miron D, Daas A, Sakran W, et al. Is omitting post urinary-tract-infection renal ultrasound safe after normal antenatal ultrasound? An observational study. Arch Dis Child 2007; 92:502.</a></li><li class="breakAll">American College of Radiology. ACR Appropriateness Criteria. Urinary Tract Infection--Child. https://acsearch.acr.org/docs/69444/Narrative/ (Accessed on July 30, 2019).</li><li><a class="nounderline abstract_t">Downs SM. UTI and watchful waiting: the courage to do nothing. Pediatrics 2014; 133:535.</a></li><li><a class="nounderline abstract_t">Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. Pediatrics 1981; 67:392.</a></li><li><a class="nounderline abstract_t">Prospective trial of operative versus non-operative treatment of severe vesicoureteric reflux in children: five years' observation. Birmingham Reflux Study Group. Br Med J (Clin Res Ed) 1987; 295:237.</a></li><li><a class="nounderline abstract_t">Smellie JM, Barratt TM, Chantler C, et al. Medical versus surgical treatment in children with severe bilateral vesicoureteric reflux and bilateral nephropathy: a randomised trial. Lancet 2001; 357:1329.</a></li><li><a class="nounderline abstract_t">Weiss R, Duckett J, Spitzer A. Results of a randomized clinical trial of medical versus surgical management of infants and children with grades III and IV primary vesicoureteral reflux (United States). The International Reflux Study in Children. J Urol 1992; 148:1667.</a></li><li><a class="nounderline abstract_t">Craig JC, Simpson JM, Williams GJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med 2009; 361:1748.</a></li><li><a class="nounderline abstract_t">Garin EH, Olavarria F, Garcia Nieto V, et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006; 117:626.</a></li><li><a class="nounderline abstract_t">Pennesi M, Travan L, Peratoner L, et al. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics 2008; 121:e1489.</a></li><li><a class="nounderline abstract_t">Roussey-Kesler G, Gadjos V, Idres N, et al. Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. J Urol 2008; 179:674.</a></li><li><a class="nounderline abstract_t">Hoberman A, Keren R. Antimicrobial prophylaxis for urinary tract infection in children. N Engl J Med 2009; 361:1804.</a></li><li><a class="nounderline abstract_t">Roberts KB, AAP Subcommittee on Urinary Tract Infection. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 2014; 371:1071.</a></li><li><a class="nounderline abstract_t">Hoberman A, Wald ER. Treatment of urinary tract infections. Pediatr Infect Dis J 1999; 18:1020.</a></li><li><a class="nounderline abstract_t">Mazzi S, Rohner K, Hayes W, Weitz M. Timing of voiding cystourethrography after febrile urinary tract infection in children: a systematic review. Arch Dis Child 2020; 105:264.</a></li><li><a class="nounderline abstract_t">Craig JC, Wheeler DM, Irwig L, Howman-Giles RB. How accurate is dimercaptosuccinic acid scintigraphy for the diagnosis of acute pyelonephritis? A meta-analysis of experimental studies. J Nucl Med 2000; 41:986.</a></li><li><a class="nounderline abstract_t">Hansson S, Dhamey M, Sigström O, et al. Dimercapto-succinic acid scintigraphy instead of voiding cystourethrography for infants with urinary tract infection. J Urol 2004; 172:1071.</a></li><li><a class="nounderline abstract_t">Preda I, Jodal U, Sixt R, et al. Normal dimercaptosuccinic acid scintigraphy makes voiding cystourethrography unnecessary after urinary tract infection. J Pediatr 2007; 151:581.</a></li><li><a class="nounderline abstract_t">Tseng MH, Lin WJ, Lo WT, et al. Does a normal DMSA obviate the performance of voiding cystourethrography in evaluation of young children after their first urinary tract infection? J Pediatr 2007; 150:96.</a></li><li><a class="nounderline abstract_t">Pohl HG, Belman AB. The "top-down" approach to the evaluation of children with febrile urinary tract infection. Adv Urol 2009; :783409.</a></li><li><a class="nounderline abstract_t">Routh JC, Grant FD, Kokorowski PJ, et al. Economic and radiation costs of initial imaging approaches after a child's first febrile urinary tract infection. Clin Pediatr (Phila) 2012; 51:23.</a></li><li><a class="nounderline abstract_t">Montini G, Zucchetta P, Tomasi L, et al. Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1. Pediatrics 2009; 123:e239.</a></li><li><a class="nounderline abstract_t">Marks SD, Gordon I, Tullus K. Imaging in childhood urinary tract infections: time to reduce investigations. Pediatr Nephrol 2008; 23:9.</a></li><li><a class="nounderline abstract_t">Shaikh N, Haralam MA, Kurs-Lasky M, Hoberman A. Association of Renal Scarring With Number of Febrile Urinary Tract Infections in Children. JAMA Pediatr 2019; 173:949.</a></li><li><a class="nounderline abstract_t">Salo J, Ikäheimo R, Tapiainen T, Uhari M. Childhood urinary tract infections as a cause of chronic kidney disease. Pediatrics 2011; 128:840.</a></li><li><a class="nounderline abstract_t">Martinell J, Lidin-Janson G, Jagenburg R, et al. Girls prone to urinary infections followed into adulthood. Indices of renal disease. Pediatr Nephrol 1996; 10:139.</a></li><li><a class="nounderline abstract_t">Wennerström M, Hansson S, Hedner T, et al. Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood. J Hypertens 2000; 18:485.</a></li><li><a class="nounderline abstract_t">Smellie JM, Prescod NP, Shaw PJ, et al. Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults. Pediatr Nephrol 1998; 12:727.</a></li></ol></div><div id="topicVersionRevision">Topic 5991 Version 90.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529459" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Imaging studies after a first febrile urinary tract infection in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620413" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Urinary tract infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873693" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18159059" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Does this child have a urinary tract infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710324" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Development and Validation of a Calculator for Estimating the Probability of Urinary Tract Infection in Young Febrile Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27455161" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early Antibiotic Treatment for Pediatric Febrile Urinary Tract Infection and Renal Scarring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390264" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral versus initial intravenous therapy for urinary tract infections in young febrile children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25066627" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antibiotics for acute pyelonephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21358894" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Are oral antibiotics equivalent to intravenous antibiotics for the initial management of pyelonephritis in children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30131437" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Emergency Department Revisits After an Initial Parenteral Antibiotic Dose for UTI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940735" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reaffirmation of AAP Clinical Practice Guideline: The Diagnosis and Management of the Initial Urinary Tract Infection in Febrile Infants and Young Children 2-24 Months of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611232" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716786" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pediatric urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162689" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outpatient management of young febrile infants with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162689" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outpatient management of young febrile infants with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415079" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Admit Versus Discharge-A Cost Analysis of Infants 29 to 60 Days Old With Febrile Urinary Tract Infection at Low Risk for Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098155" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Febrile infants with urinary tract infections at very low risk for adverse events and bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26794472" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predictors of Antimicrobial Resistance among Pathogens Causing Urinary Tract Infection in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980184" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26969273" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antimicrobial Resistance and Urinary Tract Infection Recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29954832" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16203936" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antibiotic resistance patterns in children hospitalized for urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047236" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antibiotic resistance patterns of community-acquired urinary tract infections in children with vesicoureteral reflux receiving prophylactic antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23919903" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Urinary tract infections caused by community-acquired extended-spectrumβ-lactamase-producing and nonproducing bacteria: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17622599" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194282" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24362645" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795142" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antimicrobial prophylaxis for children with vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074149" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365328" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741093" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antimicrobial Resistance Among Uropathogens That Cause Childhood Community-acquired Urinary Tract Infections in Central Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716722" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Increasing antibiotic resistance among urinary tract isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10352632" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk factors for resistance to "first-line" antimicrobials among urinary tract isolates of Escherichia coli in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502928" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Characteristics of first urinary tract infection with fever in children: a prospective clinical and imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24825869" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antibiotic susceptibility of common pediatric uropathogens in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29385442" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of risk factors for, and prevalence of, antibiotic resistance in contaminating and pathogenic urinary Escherichia coli in children in primary care: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472951" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Extended-Spectrum Beta-Lactamase Bacteria From Urine Isolates in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369720" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antibiotic resistance patterns of outpatient pediatric urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956854" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12670848" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antibiotic resistance patterns of uropathogens in pediatric emergency department patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598381" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623269" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Urinary tract infection in small outpatient children: the influence of age and gender on resistance to oral antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428232" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28899877" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multiresistant E. coli urine infections in children: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872277" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : High Rates of Antibiotic Nonsusceptibility in Gram-negative Urinary Tract Infection in Children With Risk Factors Occurring in the Preceding Month: Considerations for Choosing Empiric Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37358858" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Short-Course Therapy for Urinary Tract Infections in Children: The SCOUT Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953316" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical Response to Discordant Therapy in Third-Generation Cephalosporin-Resistant UTIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15185189" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antimicrobial resistance among enteric pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917238" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689346" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689346" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831830" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diagnosis and management of pediatric urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303849" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Empiric use of cefepime in the treatment of serious urinary tract infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156358" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624812" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Length of intravenous antibiotic therapy and treatment failure in infants with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097611" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Trends in Intravenous Antibiotic Duration for Urinary Tract Infections in Young Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31431480" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Parenteral Antibiotic Therapy Duration in Young Infants With Bacteremic Urinary Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10799623" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nonresponders: prolonged fever among infants with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15789210" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Imaging strategies in pediatric urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18845984" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Renal abscess in children: a 10-year clinical and radiologic experience in a tertiary medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272596" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Repeat urine cultures in children who are admitted with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662582" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Follow-up urine cultures and fever in children with urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662582" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Follow-up urine cultures and fever in children with urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662582" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Follow-up urine cultures and fever in children with urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025941" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Imaging and treatment strategies for children after first urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21059720" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk of renal scarring in children with a first urinary tract infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768669" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Renal function 16 to 26 years after the first urinary tract infection in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15970603" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Time to review the value of imaging after urinary tract infection in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15970618" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The presence of vesicoureteric reflux does not identify a population at risk for renal scarring following a first urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769296" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Further investigation of confirmed urinary tract infection (UTI) in children under five years: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25089634" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412033" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Section on Urology response to new Guidelines for the diagnosis and management of UTI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412032" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Response to the AAP Section on Urology concerns about the AAP Urinary Tract Infection Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439905" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23768525" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Utility of screening ultrasound after first febrile UTI among patients with clinically significant vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515519" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Ultrasound as a screening test for genitourinary anomalies in children with UTI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27378557" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004557" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Accuracy of Ultrasound in Identifying Renal Scarring as Compared to DMSA Scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34864050" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Kidney Echogenicity and Vesicoureteral Reflux in Children with Febrile Urinary Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977988" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16717085" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical and laboratory characteristics of non-E. coli urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9924638" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Should renal ultrasonography be done routinely in children with first urinary tract infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37252727" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Kidney Ultrasonography After First Febrile Urinary Tract Infection in Children: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1747613" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227808" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Is omitting post urinary-tract-infection renal ultrasound safe after normal antenatal ultrasound? An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227808" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Is omitting post urinary-tract-infection renal ultrasound safe after normal antenatal ultrasound? An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515509" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : UTI and watchful waiting: the courage to do nothing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7017578" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888509" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prospective trial of operative versus non-operative treatment of severe vesicoureteric reflux in children: five years' observation. Birmingham Reflux Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343739" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Medical versus surgical treatment in children with severe bilateral vesicoureteric reflux and bilateral nephropathy: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1433585" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Results of a randomized clinical trial of medical versus surgical management of infants and children with grades III and IV primary vesicoureteral reflux (United States). The International Reflux Study in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19864673" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Antibiotic prophylaxis and recurrent urinary tract infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510640" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490378" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18082208" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19864680" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Antimicrobial prophylaxis for urinary tract infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207773" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Antimicrobial prophylaxis for children with vesicoureteral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571443" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31466991" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Timing of voiding cystourethrography after febrile urinary tract infection in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10855622" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : How accurate is dimercaptosuccinic acid scintigraphy for the diagnosis of acute pyelonephritis? A meta-analysis of experimental studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15311040" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Dimercapto-succinic acid scintigraphy instead of voiding cystourethrography for infants with urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035134" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Normal dimercaptosuccinic acid scintigraphy makes voiding cystourethrography unnecessary after urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17188624" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Does a normal DMSA obviate the performance of voiding cystourethrography in evaluation of young children after their first urinary tract infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19343189" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The "top-down" approach to the evaluation of children with febrile urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868595" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Economic and radiation costs of initial imaging approaches after a child's first febrile urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139086" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Value of imaging studies after a first febrile urinary tract infection in young children: data from Italian renal infection study 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17668243" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Imaging in childhood urinary tract infections: time to reduce investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31381021" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Association of Renal Scarring With Number of Febrile Urinary Tract Infections in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987701" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Childhood urinary tract infections as a cause of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703696" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Girls prone to urinary infections followed into adulthood. Indices of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10779101" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874316" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
